science and politics

Biotech, Policy, and the 2012 Election with Lee Silver

Podcast brought to you by: See your company name here. - Promote your organization and align it with today's latest trends.


Lee M. Silver, PhD, Princeton University Bio and Contact Info

Listen (5:56) What is at stake for biotech in the 2012 election?

Listen (2:05) What do you say to those who insist science should not be on the dole?

Listen (7:39) What is your take on the recent report by Obama's Bioethics Panel?

Listen (6:14) California's Prop 37 a "stupid" thing

Listen (5:56) Controversy over bird flu virus not an easy one

Listen (11:54) GenePeeks offers better filtering at sperm banks

Listen (1:13) Is the consumer genetics movement over?

Lee Silver is an expert on biotech and public policy at Princeton University. He is the author of several books including, Remaking Eden: How Genetic Engineering and Cloning Will Remake the American Family. No time is better to get the thoughts of the renowned author than election season.

Silver has been outspoken about biotech policy differences between the Bush and the Obama administrations, and we ask him to extend his thoughts on the upcoming election. He also weighs in on California's Prop 37 requiring the labeling of genetically modified foods. Lee says it's a "stupid" thing. That even if the law is passed, it is not even doable.

Other topics include the controversy over the modification of the bird flu virus and whether the science should have been published, and GenePeeks, Silver's new company that is creating virtual children.

Science and the 2012 Election with Bill Frezza


Bill Frezza, Columnist, Bio-IT World, General Partner at Adams Capital Management Bio and Contact Info

Chapters: (Advance the marker)

0:37 Will you rate the presidential candidates on science?

7:07 Let's just fund the top rate researchers

12:46 How do you measure success in the War on Cancer

15:48 Nothing has brought us more progress than the free market

17:57 What about the Manhattan Project?

22:14 How do we keep our edge in the world without strong science funding?

27:40 Who is going to fund life science start-ups?

31:55 BioLeap - designing drugs "de novo"

Bill Frezza is a venture capitalist and columnist at Forbes and Bio-IT World. As one can see from the name of his column, "The Skeptical Outsider," Bill is not shy about questioning the status quo. Today we get him to weigh in on the two presidential candidates and how the outcome of the election will affect science funding. Frezza is a free market advocate and feels that we are funding second and third rate research and creating a surplus of science PhD's. We talk about the War on Cancer and compare it to The Manhattan Project. At the end, Bill discusses the venture capital world and his own new venture, BioLeap.

A Grand Awakening: Bill Frezza, Columnist


Bill Frezza, Columnist, Bio-IT World, General Partner at Adams Capital Management Bio and Contact Info

Listen (5:15) Speaking as an outsider

Listen (7:53) Life science needs a grand awakening

Listen (4:13) Physics and math eventually takes over everything

Listen (2:16) What do you say to detractors?

Listen (11:24) PI's and their indentured servants

Bill Frezza is a Boston-based venture capitalist and a regular columnist at Bio-IT World, Forbes, and Real Clear Markets. Calling himself an outsider to the life sciences, Bill penned a column some weeks back "How to Save the Life Sciences from Technological Torpor." I ask him what he means and this leads to a discussion of what he calls a broken industry in need of some math and physics. Bill is not shy with his opinion, so we plan to have him back soon.

Customize This

New to Mendelspod?

We advance life science research, connecting people and ideas.
Register here to receive our newsletter.

or skip signup